Corporate Profile
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicine – to More >>
Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.19 (0.40%)
Intraday High$48.75
Intraday Low$47.02
Data as of 08/29/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
08/07/14Clovis Oncology Announces Second Quarter 2014 Operating Results
CO-1686 NDA submission expected by mid-2015 CO-1686 Breakthrough Therapy designation granted during Q2 Proposed INN rociletinib assigned to CO-1686 Rociletinib and rucaparib data updates to be presented at medical conferences in Fall 2014 BOULDER, Colo.--(BUSINESS WIRE)--Aug. 7, 2014-- Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for its second quarter ended June 30, 2014, and provided a... 
Printer Friendly VersionDownload PDF
07/21/14Clovis Oncology to Announce Second Quarter 2014 Financial Results and Host Webcast Conference Call on August 7
BOULDER, Colo.--(BUSINESS WIRE)--Jul. 21, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its second quarter 2014 financial results on Thursday, August 7, 2014, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis ... 
Printer Friendly VersionDownload PDF
06/23/14Clovis Oncology Announces First Patient Enrolled in TIGER2 Study
Study to evaluate CO-1686 as treatment for second-line mutant EGFR NSCLC patients with confirmed T790M resistance mutation BOULDER, Colo.--(BUSINESS WIRE)--Jun. 23, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the TIGER2 study has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor ... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.